ROSEN, NATIONAL LAWYERS, encourages Athira Pharma,


NEW YORK, August 06, 2021 (GLOBE NEWSWIRE) –

WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): ”or“ Offer ”); and / or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the “Recourse Period”), of the material August 24, 2021 lead applicant’s time limit.

SO WHAT: If you have purchased securities of Athira in accordance with and / or traceable to the IPO of the Company and / or during the Class Period, you may be entitled to compensation without payment of any fees or additional charges through a contingency fee agreement.

WHAT TO DO NEXT: To join the Athira class action lawsuit, go to or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action. A class action has already been filed. If you want to serve as the principal applicant, you must move the court no later than August 24, 2021. A principal plaintiff is a representative party acting on behalf of the other members of the class to direct the litigation.

WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies providing reviews do not have comparable experience, resources or peer recognition. Be wise in choosing the right lawyer. Rosen law firm represents investors around the world, focusing its practice on class actions in securities and derivative litigation between shareholders. Rosen law firm has secured the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds millions of dollars for investors. In 2019 alone, the company raised more than $ 438 million for investors. In 2020, founding partner Laurence Rosen was appointed by law360 as the Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuits, the Offer documents contained and the defendants made false and / or misleading statements and / or failed to disclose that: (1) Research conducted by the CEO and Chairman of the Company, Leen Kawas, was marred by the science of Kawas misconduct, including the manipulation of key data through the modification of Western blot images; (2) this purported research was the basis of Athira’s efforts to develop treatments for Alzheimer’s disease, as it laid the biological foundation that Athira used in her approach to treating Alzheimer’s disease; (3) accordingly, Athira’s intellectual property and product development for the treatment of Alzheimer’s disease were based on invalid research; and (4) as a result of the foregoing, the defendants’ positive statements about Athira’s business, operations and prospects were materially misleading and / or lacking reasonable basis. When the real details entered the market, the lawsuit claims that investors have suffered damage.

To join the Athira class action lawsuit, go to or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action.

No class has been certified. Until a group is certified, you are not represented by a lawyer unless you hire one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. The ability of an investor to participate in any potential future recovery does not depend on whether he or she is a lead applicant.

Follow us for updates on LinkedIn:, on Twitter: or on Facebook:

Lawyer advertising. Previous results do not guarantee a similar result.


Contact details:

Laurence Rosen, Esq.
Phillip Kim, Esq.
Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, New York 10016
Phone. : (212) 686-1060
Toll free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]

Source link

Leave A Reply

Your email address will not be published.